Biodexa Pharmaceuticals PLC
BDRX2.270USD
-0.030-1.30%
收盤 12/31, 16:00（美東）報價延遲15分鐘
14.06B總市值
13.02本益比TTM
關於 Biodexa Pharmaceuticals PLC 公司
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC簡介
公司代碼BDRX
公司名稱Biodexa Pharmaceuticals PLC
上市日期Dec 08, 2014
CEOStamp (Stephen A)
員工數量- -
證券類型Depository Receipt
年結日Dec 08
公司地址1 Caspian Point
城市ABINGDON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編CF10 4DQ
電話4401235888300
網址https://www.biodexapharma.com/
公司代碼BDRX
上市日期Dec 08, 2014
CEOStamp (Stephen A)
Biodexa Pharmaceuticals PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Belgium
381.00K
100.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月29日 週六
更新時間: 11月29日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
95.32%
持股股東
持股股東
佔比
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
95.32%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
2.92%
Bank and Trust
1.12%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Hedge Fund
0.07%
Research Firm
0.02%
其他
94.69%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
25
26.99K
4.36%
-3.65K
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
1.42K
0.23%
+793.00
+126.88%
Apr 01, 2024
GAMMA Investing LLC
1.35K
0.22%
+158.00
+13.23%
Sep 30, 2025
GS Capital Partners LLC
631.00
0.1%
+631.00
--
Apr 01, 2024
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
公告日期
類型
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
查看更多
常見問題
Biodexa Pharmaceuticals PLC的前五大股東是誰？
Biodexa Pharmaceuticals PLC的前五大股東如下：
Brio Capital Management LLC持有股份：16.77K佔總股份比例：2.71%。
UBS Switzerland AG持有股份：6.92K佔總股份比例：1.12%。
Abbe (Richard)持有股份：2.43K佔總股份比例：0.39%。
Bukwang Pharmaceutical Co., Ltd.持有股份：1.42K佔總股份比例：0.23%。
Melior Pharmaceuticals I, Inc.持有股份：1.42K佔總股份比例：0.23%。
Brio Capital Management LLC持有股份：16.77K佔總股份比例：2.71%。
UBS Switzerland AG持有股份：6.92K佔總股份比例：1.12%。
Abbe (Richard)持有股份：2.43K佔總股份比例：0.39%。
Bukwang Pharmaceutical Co., Ltd.持有股份：1.42K佔總股份比例：0.23%。
Melior Pharmaceuticals I, Inc.持有股份：1.42K佔總股份比例：0.23%。
Biodexa Pharmaceuticals PLC的前三大股東類型是什麼？
Biodexa Pharmaceuticals PLC 的前三大股東類型分別是：
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
有多少機構持有Biodexa Pharmaceuticals PLC(BDRX)的股份？
截至2025Q4，共有25家機構持有Biodexa Pharmaceuticals PLC的股份，合計持有的股份價值約為26.99K，占公司總股份的4.36% 。與2025Q3相比，機構持股有所增加，增幅為-0.59%。
哪個業務部門對Biodexa Pharmaceuticals PLC的收入貢獻最大？
在FY2023，--業務部門對Biodexa Pharmaceuticals PLC的收入貢獻最大，創收--，占總收入的--% 。
